Indian Prime Minister Narendra Modi Sunday discussed cooperation with Japan to combat sickle cell anaemia that is prevalent in India's tribal regions, an official said.
Modi met Shinya Yamanaka, Japan's stem cell pioneer and 2012 Nobel Prize winner, at Kyoto University and discussed treatment of the disease.
They discussed the "possibilities of sickle cell anaemia cure" and "prospects of cooperation among Indian and Japanese institutes", tweeted an external affairs ministry spokesman.
"The prime minister expressed concern over the prevalence of sickle cell anaemia, especially among tribal communities across India," a statement by the Indian government said.
Sickling decreases the cells' flexibility and results in a risk of various life threatening complications. It mostly occurs in regions where malaria is rampant.
"The prime minister urged Yamanaka to work towards a cure for this," the statement said.
Yamanaka said there were currently no Indian researchers at his institute, the Centre for iPS Cell Research and Application, and "he would like Indian scientists to conduct research at the institute".
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
